HPV vaccination coverage by Socio-Economic Status of area of residence for males aged 12-13 years in 2014

Graph 1. HPV vaccination coverage by socio-economic status of area of residence for males aged 12-13 years in 2014.

Table 1. HPV vaccination coverage by socio-economic status of area of residence for
males aged 12-13 years in 2014.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Coverage Dose 1 | Coverage Dose 2 | Coverage Dose 3 |
| Quintile 1: High SES | 87.0% | 84.7% | 79.4% |
| Quintile 2 | 84.6% | 82.1% | 76.5% |
| Quintile 3 | 83.9% | 80.9% | 75.2% |
| Quintile 4 | 83.1% | 79.9% | 73.9% |
| Quintile 5: Low SES | 80.6% | 77.0% | 70.5% |
| All Quintiles | **83.8%** | **80.9%** | **75.1%** |

# Notes:

* Data extracted from the National HPV Vaccination Program Register (HPV Register) as at July 2017.
* Includes doses that comply with the recommended vaccine dosage and administration as per the Australian Immunisation Handbook (up to 3 doses administered at prescribed intervals).
* Quintiles of socio-economic status have been assigned based on the vaccine recipient’s postcode of residence. Postcodes were allocated to quintiles of socio-economic status based on the 2011 ABS SEIFA Postal Area to Index of Relative Socioeconomic Disadvantage 2011 (cat no. 2033.0.55.001), with each quintile allocated approximately 20% of the population.
* ABS mid-year population estimates were used, with preliminary rebased data for 2013. Postal Area level estimates were derived from SA1 areas of Australia, produced as a customised consultancy by the ABS. These estimates correspond with 30 June 2001-2015 ERP by SA2 as released in Regional Population Growth, Australia, 2014-15 (cat. no. 3218.0).
* Age is age as at date of ERP estimate (30th June). Note that these estimates are for cohorts at age 12-13 and are therefore not comparable to other same year coverage estimates for those aged 15 years.
* Coverage is calculated as doses administered and reported to the HPV Register/Estimated Population expressed as a percentage.
* Excludes consumers who do not wish their details to be recorded on the HPV Register.
* The National HPV Vaccination Program initially provided quadrivalent HPV vaccine for all females aged 12-26 years as at mid 2007 (school program commenced April 2007 and GP/community program in July 2007) until end December 2009. From 2009 the Program offered HPV vaccination routinely to females in the first year of high school (usually at 12-13 years). From 2013, males were also offered HPV vaccination routinely in the first year of high school (age 12-13 years), with a catch-up program available for males aged 14-15 years in 2013 and 2014.
* HPV Vaccination doses administered through general practice and in other community settings may be incompletely notified to the HPV Register. The extent of under notification differs by jurisdiction, with the Northern Territory and Queensland expected to have the most complete notification, due to notification of doses via State based immunisation registers.